Catheter Precision to Participate in and Share Data at Upcoming Industry Conferences
FORT MILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at three upcoming conferences through April 2, 2025.
Catheter Precision will be attending the following conferences:
- (ACC) from March 29-31, 2025, in Chicago, Illinois
- (EHRA) March 30 – April 1, 2025 in Vienna, Austria
- (SIR) March 29 – April 2, 2025 in Nashville, Tennessee
During the ACC meeting, Catheter Precision’s LockeT device will be showcased in a poster abstract on March 31, 2025. This abstract will include the newest clinical data available about LockeT compared to manual compression (standard of care for hemostasis). Data from a recent study of 97 patients demonstrates that LockeT provides improvement over manual compression by decreasing time to ambulation, utilizing fewer nursing resources and providing hemostasis at a lower price point than vascular closure devices. The ACC has more than 56,000 members worldwide that include all cardiac physician specialties with a mission to transform cardiovascular care and improve heart health for all.
At both EHRA and SIR, Catheter Precision will have a booth in the exhibit halls showcasing VIVO at EHRA and LockeT at SIR. This will be the first time Catheter Precision attends a conference for interventional radiology.
EHRA brings together scientists, healthcare professionals and other players involved in arrhythmia management from all around the world with a focus on European physicians.
SIR is the premier professional organization representing interventional radiologists worldwide. With a legacy of excellence spanning decades, they are dedicated to advancing the practice of interventional radiology and enhancing patient care.
David Jenkins, CEO of Catheter Precision, said, “Attending conferences is vital part of our business model. It provides us the opportunity to meet with leaders in the field, share clinical data and meet new customers. The acceptance of an abstract at a conference as large as ACC is impressive. It further demonstrates that LockeT is a valuable product in the EP Lab. We hope to demonstrate its value to interventional radiologists at the SIR meeting as this provides the opportunity to bring LockeT to an entire new market.”
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements our hope to demonstrate LockeT’s value to interventional radiologists at the SIR meeting and our belief that the SIR meeting will provide us with the opportunity to bring LockeT to an entire new market. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to that medical practitioners and hospitals may not accept LockeT or may be otherwise committed to competing products that generate more revenue, and that royalty agreements with respect to our LockeT device will reduce any future profits from this product or procedures, as well as general risks and uncertainties impacting our business that are included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
# # #
